We first attempted to block the CD226 pathway in PBMCs from PBC patients and found that CD226 blocking could not only suppress the proliferation of T cells, but also inhibit their cytotoxic function by decreasing the expression of CD107a and reducing the cytokine production of IFN-γ and TNF-α. This evidence concerns the gene TNF and primary biliary cholangitis.